Revance The

Company Profile

Revance The had its IPO on 2014-02-06 under the ticker symbol RVNC.

The company operates in the Healthcare sector and Biotechnology industry. Revance The has a staff strength of 534 employees.

Stock update

Shares of Revance The opened at $15.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $15.13 - $16.22, and closed at $16.11.

This is a +4.41% increase from the previous day's closing price.

A total volume of 2,714,229 shares were traded at the close of the day’s session.

In the last one week, shares of Revance The have slipped by -11.29%.

Revance The's Key Ratios

Revance The has a market cap of $1.36 billion, indicating a price to book ratio of 12.3032 and a price to sales ratio of 16.289.

In the last 12-months Revance The’s revenue was $186.40 million with a gross profit of $-20388000 and an EBITDA of $-238327008. The EBITDA ratio measures Revance The's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Revance The’s operating margin was -147.87% while its return on assets stood at -29.72% with a return of equity of -2962.17%.

In Q2, Revance The’s quarterly earnings growth was a positive 0% while revenue growth was a positive 104.9%.

Revance The’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

-0.64

Its diluted EPS in the last 12-months stands at $-4.23 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.64. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Revance The’s profitability.

Revance The stock is trading at a EV to sales ratio of 16.9625 and a EV to EBITDA ratio of -7.9266. Its price to sales ratio in the trailing 12-months stood at 16.289.

Revance The stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$597.54 million

Total Liabilities

$74.08 million

Operating Cash Flow

$-39532000.00

Capital Expenditure

$266000

Dividend Payout Ratio

0%

Revance The ended 2024 with $597.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $597.54 million while shareholder equity stood at $26.79 million.

Revance The ended 2024 with $0 in deferred long-term liabilities, $74.08 million in other current liabilities, 88000.00 in common stock, $-1881485000.00 in retained earnings and $77.18 million in goodwill. Its cash balance stood at $141.24 million and cash and short-term investments were $319.72 million. The company’s total short-term debt was $20,766,000 while long-term debt stood at $380.35 million.

Revance The’s total current assets stands at $378.95 million while long-term investments were $0 and short-term investments were $178.49 million. Its net receivables were $17.04 million compared to accounts payable of $8.35 million and inventory worth $34.45 million.

In 2024, Revance The's operating cash flow was $-39532000.00 while its capital expenditure stood at $266000.

Comparatively, Revance The paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$16.11

52-Week High

$37.98

52-Week Low

$15.13

Analyst Target Price

$40.55

Revance The stock is currently trading at $16.11 per share. It touched a 52-week high of $37.98 and a 52-week low of $37.98. Analysts tracking the stock have a 12-month average target price of $40.55.

Its 50-day moving average was $20.62 and 200-day moving average was $27.19 The short ratio stood at 9.83 indicating a short percent outstanding of 0%.

Around 243.9% of the company’s stock are held by insiders while 9712.4% are held by institutions.